Moreover, the MONALEESA-2 study was a phase III, randomised clinical trial (1:1) which included 668 postmenopausal women with advanced breast cancer, positive hormone receptors, and HER-2 negative. This evidence concerns the gene NR4A1 and breast carcinoma.